SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics Prakash Deedwania Editorial 30 August 2021 Pages: 1 - 4
Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER Folkert H. van BruggenHendrika J. Luijendijk Commentary Open access 19 May 2021 Pages: 5 - 8
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis Adrija HajraManasvi GuptaDhrubajyoti Bandyopadhyay Leading Article 24 November 2021 Pages: 9 - 26
A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option Manasvi GuptaSubuhi KaulRaktim K. Ghosh Review Article 19 May 2021 Pages: 27 - 33
Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Utkarsh OjhaLenisse ReyesHenock Saint-Jacques Review Article 30 June 2021 Pages: 35 - 46
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent Jennifer HardyStephanie NimanRushab Choksi Review Article 07 September 2021 Pages: 47 - 54
Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis Taha AhmedAlla Y. GrigorianAdrian W. Messerli Review Article 29 May 2021 Pages: 55 - 67
Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs Mei QiuLiang-Liang DingHai-Rong Zhou Systematic Review 07 July 2021 Pages: 69 - 81
The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery Andre LamyWesley TongP. J. Devereaux Original Research Article 26 July 2021 Pages: 83 - 91
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective Ivar S. JensenElizabeth WuDeepak L. Bhatt Original Research Article Open access 31 July 2021 Pages: 93 - 104
Correction to: Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis Adrija HajraManasvi GuptaDhrubajyoti Bandyopadhyay Correction 21 December 2021 Pages: 105 - 105
Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent Jennifer HardyStephanie NimanRushab Choksi Correction 11 December 2021 Pages: 107 - 107
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction Hannah A. Blair Correction Open access 02 December 2021 Pages: 109 - 109
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS Patrick BlinCaroline Dureau-PourninNicholas Moore Correction 21 December 2021 Pages: 111 - 111
